CELEX: 32021M10004
Language: en
Date: 2021-02-10 00:00:00
Title: Commission Decision of 10/02/2021 declaring a concentration to be compatible with the common market (Case No COMP/M.10004 - EQT / ZENTRICITY / CAJELO / RECIPHARM) according to Council Regulation (EC) No 139/2004 (Only the English text is authentic)

EUROPEAN COMMISSION
                                                              Brussels, 10.2.2021
                                                              C(2021) 1003 final
                                                                               PUBLIC VERSION
                                                              EQT Fund Management S.à r.l.
                                                              26A, Boulevard Royal
                                                              L-2449 Luxembourg
                                                              Luxembourg
                                                              Cajelo Invest Ltd.
                                                              Chm de Pra Micaud 43
                                                              1936 Verbier
                                                              Switzerland
                                                              Zentricity Holding AB.
                                                              Strandpromenaden 9
                                                              131 50 Saltsjö-Duvnäs
                                                              Sweden
Subject:        Case M.10004 - EQT / ZENTRICITY / CAJELO / RECIPHARM
                Commission decision pursuant to Article 6(1)(b) of Council Regulation
                                        1
                (EC) No 139/2004 and Article 57 of the Agreement on the European
                                    2
                Economic Area
Dear Sir or Madam,
1.      On 18 January 2021, the European Commission received notification of a proposed
        concentration pursuant to Article 4 of the Merger Regulation by which EQT IX
        Collect EUR SCSp and EQT IX Collect USD SCSp (together "EQT IX") controlled
        by EQT Fund Management S.à r.l. (“EQT”, Luxembourg), Zentricity Holding AB
        (“Zentricity”, Sweden), which is controlled by private individual Thomas Eldered, and
        Cajelo Invest Ltd (“Cajelo”, Cyprus), which is controlled by private individual Lars
        Backsell, acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint
1       OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’). With effect from 1 December 2009, the Treaty on
        the Functioning of the European Union (‘TFEU’) has introduced certain changes, such as the
        replacement of ‘Community’ by ‘Union’ and ‘common market’ by ‘internal market’. The terminology
        of the TFEU will be used throughout this decision.
2       OJ L 1, 3.1.1994, p. 3 (the ‘EEA Agreement’).
Commission européenne, DG COMP MERGER REGISTRY, 1049 Bruxelles, BELGIQUE
Europese Commissie, DG COMP MERGER REGISTRY, 1049 Brussel, BELGIË
Tel: +32 229-91111. Fax: +32 229-64301. E-mail: COMP-MERGER-REGISTRY@ec.europa.eu.
 ---pagebreak---    control of the whole of Recipharm AB (“Recipharm”, Sweden). The concentration is
   accomplished by way of public bid announced on 14 December 2020. 3
2. The business activities of the undertakings concerned are:
   −    for EQT: private equity funds that invest in companies across the world, which
        amongst others control EQT IX, an investment fund investing primarily in
        Europe, with a focus on Northern Europe;
   −    for Zentricity: investment company focusing on investing in pharmaceutical
        companies primarily in Sweden, which is controlled by private individual Thomas
        Eldered, who also controls Empros Pharma AB, a pharmaceutical company,
        Flerie Creations Ltd. and Flerie Invest AB;
   −    for Cajelo: investment company that is controlled by private individual Lars
        Backsell, who also controls Glims Marketing Ltd. and Rohirrim AB, a horse
        breeding company;
   −    for Recipharm: contract development and manufacturing organization, providing
        drug development and manufacturing services globally to the pharmaceutical
        industry (e.g. for finished dose pharmaceuticals, active pharmaceutical
        ingredients and clinical trial materials for customers in the pharmaceutical
        industry), as well as packaging services and logistics services.
3. After examination of the notification, the European Commission has concluded that
   the notified operation falls within the scope of the Merger Regulation and of
   paragraph 5(c) of the Commission Notice on a simplified procedure for treatment of
   certain concentrations under Council Regulation (EC) No 139/2004. 4
4. For the reasons set out in the Notice on a simplified procedure, the European
   Commission has decided not to oppose the notified operation and to declare it
   compatible with the internal market and with the EEA Agreement. This decision is
   adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of
   the EEA Agreement.
                                                           For the Commission
                                                           (Signed)
                                                           Olivier GUERSENT
                                                           Director-General
3  Publication in the Official Journal of the European Union No C 029, 26.01.2021, p. 4.
4  OJ C 366, 14.12.2013, p. 5.
                                                       2